NCT05918055View on ClinicalTrials.gov

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

KPT-8602

5-10 mg PO daily for 10-14 days based on dose level

DRUG

Inqovi

Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT05918055 - Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter